A vs. BMRN: Agilent vs. BioMarin Pharmaceutical Stock Comparison

November 11, 2026

How do Agilent (A) and BioMarin Pharmaceutical (BMRN) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Agilent (A) and BioMarin Pharmaceutical (BMRN) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but A is classified in Life Sciences Tools & Services while BMRN is classified in Biotechnology.

Company profile comparison for Agilent (A) and BioMarin Pharmaceutical (BMRN)
Profile Item	A	BMRN
Name	AgileThought, Inc. Class A Common Stock	BioMarin Pharmaceutical Inc.
Country/Region	United States	United States
GICS Sector	Health Care	Health Care
GICS Industry Group	Pharmaceuticals, Biotechnology & Life Sciences	Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry	Life Sciences Tools & Services	Biotechnology
GICS Sub-Industry	Life Sciences Tools & Services	Biotechnology
Market Capitalization	49.28 billion USD	10.85 billion USD
Currency	USD	USD
Exchange	NYSE	Nasdaq
Listing Date	November 18, 1999	July 26, 1999
Security Type	Common Stock	Common Stock

Price Performance

Cumulative Growth

BMRN

GSPC

Agilent (A) vs. BioMarin Pharmaceutical (BMRN), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…

Trailing total returns for Agilent (A) and BioMarin Pharmaceutical (BMRN). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…

Calendar-year total returns for Agilent (A) and BioMarin Pharmaceutical (BMRN). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Agilent (A) and BioMarin Pharmaceutical (BMRN)
Metric	A	BMRN
Total Return (1Y)	22.92%	8.82%
Total Return (3Y, Annualized)	19.33%	-12.54%
Total Return (5Y, Annualized)	3.03%	-7.51%

Risk Profile

Drawdown History

BMRN

GSPC

Agilent (A) vs. BioMarin Pharmaceutical (BMRN), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…

Distribution of monthly total returns for Agilent (A) and BioMarin Pharmaceutical (BMRN). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Agilent (A) and BioMarin Pharmaceutical (BMRN)
Metric	A	BMRN
Volatility (1Y, Annualized)	33.10%	35.50%
Beta (5Y)	1.22	0.24
Max Drawdown (5Y)	-38.09%	-57.64%
Avg. Volume (3M)	2.25M	2.28M

Risk-Adjusted Performance

Risk-Return Positioning

A and BMRN are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Agilent (A) and BioMarin Pharmaceutical (BMRN)
Metric	A	BMRN
Sharpe Ratio (1Y)	0.56	0.13
Sortino Ratio (1Y)	0.96	0.23

Profitability

ROE (TTM)

BioMarin Pharmaceutical (BMRN) reports a negative ROE of -0.31%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Agilent (A) reports 20.97%, ranking against industry peers normally.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

20.97%

Max: 109.18%
A: 20.97%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

BMRN

Pharmaceuticals, Biotechnology & Life Sciences industry group

-0.31%

Max: 109.18%
Q3: 6.23%
BMRN: -0.31%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

Agilent (A) vs. BioMarin Pharmaceutical (BMRN): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

BioMarin Pharmaceutical (BMRN) reports a negative net margin of -0.52%, usually indicating a net loss over the period. Meanwhile Agilent (A) reports 19.53%, ranking against industry peers normally.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

19.53%

A: 19.53%
Max: 18.05%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

BMRN

Pharmaceuticals, Biotechnology & Life Sciences industry group

-0.52%

Max: 18.05%
Q3: 4.78%
Median: 0.00%
BMRN: -0.52%
Q1: -4.14%
Min: -17.05%

Agilent (A) vs. BioMarin Pharmaceutical (BMRN): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Both Agilent (A) at 25.56% and BioMarin Pharmaceutical (BMRN) at 26.58% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

25.56%

Max: 83.12%
A: 25.56%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

BMRN

Pharmaceuticals, Biotechnology & Life Sciences industry group

26.58%

Max: 83.12%
BMRN: 26.58%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

Agilent (A) vs. BioMarin Pharmaceutical (BMRN): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Agilent (A) and BioMarin Pharmaceutical (BMRN)
Metric	A	BMRN
ROE (TTM)	20.97%	-0.31%
ROA (TTM)	8.63%	3.89%
Net Margin (TTM)	19.53%	-0.52%
Operating Margin (TTM)	25.56%	26.58%
Gross Margin (TTM)	53.65%	53.21%

Growth

Revenue Growth

Both Agilent (A) at 6.73% and BioMarin Pharmaceutical (BMRN) at 12.87% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Agilent (A) vs. BioMarin Pharmaceutical (BMRN): A comparison of their Revenue Growth across different time periods.

EPS Growth

Both Agilent (A) at 3.16% and BioMarin Pharmaceutical (BMRN) at -18.55% land near their industries' usual EPS growth ranges, so bottom-line momentum looks broadly in line with peers on both sides.

Agilent (A) vs. BioMarin Pharmaceutical (BMRN): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Agilent (A) and BioMarin Pharmaceutical (BMRN)
Metric	A	BMRN
Revenue Growth (YoY)	6.73%	12.87%
Revenue Growth (3Y CAGR)	0.48%	15.40%
EPS Growth (YoY)	3.16%	-18.55%
EPS Growth (3Y CAGR)	3.02%	33.89%

Financial Strength

Current Ratio (MRQ)

Both Agilent (A) at 2.05 and BioMarin Pharmaceutical (BMRN) at 2.44 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.05

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
A: 2.05
Min: 0.10

BMRN

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.44

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
BMRN: 2.44
Min: 0.10

Agilent (A) vs. BioMarin Pharmaceutical (BMRN): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Agilent (A) at 0.56 carries an industry-typical debt-to-equity mix, while BioMarin Pharmaceutical (BMRN) at 0.67 uses more debt funding than most peers.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.56

Max: 1.42
Q3: 0.65
A: 0.56
Median: 0.15
Q1: 0.02
Min: 0.00

BMRN

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.67

Max: 1.42
BMRN: 0.67
Q3: 0.65
Median: 0.15
Q1: 0.02
Min: 0.00

Agilent (A) vs. BioMarin Pharmaceutical (BMRN): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Agilent (A) and BioMarin Pharmaceutical (BMRN)
Metric	A	BMRN
Current Ratio (MRQ)	2.05	2.44
Debt / Equity (MRQ)	0.56	0.67
Net Debt / EBITDA	1.15	4.04

Dividends

Dividend Yield (TTM)

BioMarin Pharmaceutical (BMRN) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Agilent (A) reports a yield of 0.59%, ranking against industry peers normally.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.59%

A: 0.59%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

BMRN

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

BMRN: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Agilent (A) vs. BioMarin Pharmaceutical (BMRN): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

BioMarin Pharmaceutical (BMRN) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Agilent (A) reports a payout of 19.98%, ranking against industry peers normally.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

19.98%

A: 19.98%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

BMRN

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

BMRN: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Agilent (A) vs. BioMarin Pharmaceutical (BMRN): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Agilent (A) and BioMarin Pharmaceutical (BMRN)
Metric	A	BMRN
Dividend Yield (TTM)	0.59%	0.00%
Dividend Payout Ratio (TTM)	19.98%	0.00%

Valuation

P/E Ratio (TTM)

An earnings multiple is available for just one side: Agilent (A) trades at 34.47 times trailing earnings, ranked against its peers, while BioMarin Pharmaceutical (BMRN) has no P/E ratio this period.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

34.47

Max: 85.34
Q3: 43.46
A: 34.47
Median: 26.69
Q1: 13.30
Min: 0.07

BMRN

Pharmaceuticals, Biotechnology & Life Sciences industry group

Max: 85.34
Q3: 43.46
Median: 26.69
Q1: 13.30
Min: 0.07
BMRN: --

Agilent (A) vs. BioMarin Pharmaceutical (BMRN): BMRN does not report P/E ratio, so it has no value marker; A is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

P/S Ratio (TTM)

BioMarin Pharmaceutical (BMRN) at 2.97 sits in the cheaper P/S ratio quartile while Agilent (A) at 6.68 prices around its industry’s middle — BMRN costs less per dollar of sales, though read it alongside growth and margins.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.68

Max: 58.18
Q3: 25.77
Median: 7.30
A: 6.68
Q1: 3.01
Min: 0.01

BMRN

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.97

Max: 58.18
Q3: 25.77
Median: 7.30
Q1: 3.01
BMRN: 2.97
Min: 0.01

Agilent (A) vs. BioMarin Pharmaceutical (BMRN): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

BioMarin Pharmaceutical (BMRN) at 1.73 is valued about in line with its industry on P/B ratio, while Agilent (A) at 6.69 carries an above-peer premium to book — A is pricier on assets.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.69

Max: 13.53
A: 6.69
Q3: 6.54
Median: 3.25
Q1: 1.69
Min: -5.59

BMRN

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.73

Max: 13.53
Q3: 6.54
Median: 3.25
BMRN: 1.73
Q1: 1.69
Min: -5.59

Agilent (A) vs. BioMarin Pharmaceutical (BMRN): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Agilent (A) and BioMarin Pharmaceutical (BMRN)
Metric	A	BMRN
P/E Ratio (TTM)	34.47	--
P/S Ratio (TTM)	6.68	2.97
P/B Ratio (MRQ)	6.69	1.73
Free Cash Flow Yield (TTM)	2.15%	-0.15%